Effect of Diallyl Trisulfide on the Pharmacokinetics of Nifedipine in Rats

Journal of Food Science

Volumn 76, Issue 1, 2011, Pages

  Wang, Yue ^a   Zou, Mei Juan ^a   Zhao, Nan ^a   Ren, Jun Gang ^a,b   Zhou, Hong ^a   Cheng, Gang ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b HARBIN UNIVERSITY OF COMMERCE   (China)

Author keywords

Diallyl trisulfide; Food drug interaction; Nifedipine; Pharmacokinetics

Indexed keywords

ALLYL COMPOUND; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIALLYL TRISULFIDE; NIFEDIPINE; PLANT EXTRACT; SULFIDE; VASODILATOR AGENT;

ANIMAL; ARTICLE; BIOAVAILABILITY; BLOOD; CHEMISTRY; DIET SUPPLEMENTATION; FOOD DRUG INTERACTION; GARLIC; HALF LIFE TIME; MALE; METABOLIC CLEARANCE RATE; PLANT ROOT; RANDOMIZATION; RAT; REPRODUCIBILITY; SPRAGUE DAWLEY RAT; TIME;

ALLYL COMPOUNDS; ANIMALS; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; DIETARY SUPPLEMENTS; FOOD-DRUG INTERACTIONS; GARLIC; HALF-LIFE; MALE; METABOLIC CLEARANCE RATE; NIFEDIPINE; PLANT EXTRACTS; PLANT ROOTS; PLATELET AGGREGATION INHIBITORS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SULFIDES; TIME FACTORS; VASODILATOR AGENTS;

ALLIUM SATIVUM; RATTUS;

EID: 78651456548     PISSN: 00221147     EISSN: 17503841     Source Type: Journal    
DOI: 10.1111/j.1750-3841.2010.01960.x     Document Type: Article

References (26)

1. Bailey DG, Arnold JM, Spence JD. 1994. Grapefruit juice and drugs. How significant is the interaction Clin Pharmacokinet 26(2):91-8.
2. Bailey DG, Spence JD, Munoz C, Arnold JM. 1991. Interaction of citrus juices with felodipine and nifedipine. Lancet 337(8736):268-9.
3. Bordia A, Verma SK, Srivastava KC. 1996. Effect of garlic on platelet aggregation in humans: a study in healthy subjects and patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 55(3):201-5.
4. Chan KC, Yin MC, Chao WJ. 2007. Effect of diallyl trisulfide-rich garlic oil on blood coagulation and plasma activity of anticoagulation factors in rats. Food Chem Toxicol 45(3):502-7.
5. Doherty MM, Charman WN. 2002. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism Clin Pharmacokinet 41(4):235-53.
6. Dorababu M, Nishimura A, Prabha T, Naruhashi K, Sugioka N, Takada K, Shibata N. 2009. Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. Biomed Pharmacother 63(9):697-702.
7. Dresser GK, Spence JD, Bailey DG. 2000. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38(1):41-57.
8. Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT, Gallicano KD, Choudri S. 2001. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 4(2):176-84.
9. Fukao T, Hosono T, Misawa S, Seki T, Ariga T. 2004. The effects of allyl sulfides on the induction of phase II detoxification enzymes and liver injury by carbon tetrachloride. Food Chem Toxicol 42(5):743-9.
10. Gelal A, Eminoglua O, Kaplana YC, Kalkana S. 2007. Effect of subacute methyl parathion administration on the pharmacokinetics and pharmacodynamics of nifedipine in rats. Environ Toxicol Pharmacol 24(1):1-4.
11. Grundy JS, Eliot LA, Foster RT. 1997. Extrahepatic first-pass metabolism of nifedipine in the rat. Biopharm Drug Dispos 18(6):509-22.
12. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. 2002. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 72(3):276-87.
13. Hensrud DD, Engle DD, Scheitel SM. 1999. Underreporting the use of dietary supplements and nonprescription medications among patients undergoing a periodic health examination. Mayo Clin Proc 74(5):443-7.
14. Iwao T, Inoue K, Hayashi Y, Yuasa H, Watanabe J. 2002. Metabolic extraction of nifedipine during absorption from the rat small intestine. Drug Metab Pharmacokinet 17(6):546-53.
15. Klepser TB, Doucette WR, Horton MR, Buys LM, Ernst ME, Ford JK, Hoehns JD, Kautzman HA, Logemann CD, Swegle JM, Ritho M, Klepser ME. 2000. Assessment of patients' perceptions and beliefs regarding herbal therapies. Pharmacotherapy 20(1):83-7.
16. Knox J, Gaster B. 2007. Dietary supplements for the prevention and treatment of coronary artery disease. J Altern Complement Med 13(1):83-95.
17. Koley AP, Robinson RC, Markowitz A, Friedman FK. 1997. Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4. Biochem Pharmacol 53(4):455-60.
18. Kwak MK, Kim SG, Kim ND. 1995. Effects of garlic oil on rat hepatic P4502E1 expression. Xenobiotica 25(10):1021-9.
19. Lin JH, Chiba M, Baillie TA. 1999. Is the role of the small intestine in first-pass metabolism overemphasized Pharmacol Rev 51(2):135-58.
20. Nabekura T, Kamiyama S, Kitagawa S. 2005. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem Biophys Res Commun 327(3):866-70.
21. Pan J, Hong JY, Ma BL, Ning SM, Paranawithana SR, Yang CS. 1993. Transcriptional activation of cytochrome P450 2B1/2 genes in rat liver by diallyl sulfide, a compound derived from garlic. Arch Biochem Biophys 302(2):337-42.
22. Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, George CF. 1995. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 40(1):51-8.
23. Reicks MM, Crankshaw DL. 1996. Modulation of rat hepatic cytochrome P-450 activity by garlic organosulfur compounds. 25(3):241-8.
24. Singh SV, Pan SS, Srivastava SK, Xia H, Hu X, Zaren HA, Orchard JL. 1998. Differential induction of NAD(P)H: quinone oxidoreductase by anti-carcinogenic organosulfides from garlic. Biochem Biophys Res Commun 244(3):917-20.
25. Tattelman E. 2005. Health effects of garlic. Am Fam Physician 72(1):103-6.
26. Wacher VJ, Wu CY, Benet LZ. 1995. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13(3):129-34.